Close menu




February 23rd, 2021 | 09:20 CET

TUI, Marble Financial, Zalando - Does it work?

  • Investments
Photo credits: pixabay.com

The customer is king! Here, desire and reality sometimes diverge quite a bit. Companies that know, understand and fulfill their customers and their customers' wishes have a greater chance of operating profitably. We introduce you to three companies that focus on very different target groups. The question arises: happy customers = happy shareholders? We will tell you where the equation works out.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: DE000TUAG000 , CA5660551097 , DE000ZAL1111

Table of contents:


    TUI AG - Pendulum of the Pandemic

    Europe's leading tourism group is suffering enormously from the Corona pandemic. Several capital injections in recent months have ensured that the lights have not gone out at TUI. The share price of the holding Company was quoted below EUR 2 at times. Unsurprisingly, an improvement in the pandemic situation is quickly reflected in the share price. Yesterday, the share price was able to rise in the wake of positive news. A study by the Israeli Ministry of Health shows that the BioNTech vaccine has a 90% probability of stopping the virus's transmission. This news takes away a lot of uncertainty.

    On February 9, the Group published its latest quarterly data from October to December. Since the fiscal year deviates from the calendar year, these represent the first quarter. The figures are devastating: a drop in sales of 88% to EUR 468 million and the increase in the loss from EUR 105 million to EUR 813 million. Although the Company succeeded in securing a further financing package worth EUR 1.8 billion in December and thus, according to the Company, has sufficient liquidity until a recovery sets in, the Group's crisis is not yet over. TUI expects a significant recovery in the coming summer season and refers to bookings of already 2.8 million guests.

    Given a negative equity ratio of 5% as of the balance sheet date and net debt of around EUR 7 billion, the Group must return to profitability soon. A later recovery of the travel industry than assumed could be dangerous in terms of debt and liquidity. Even if state aid and capital measures were to retake effect, shareholders could be massively diluted. The stock will undoubtedly be buoyed in the near term by sentiment as vaccinations and the pandemic fight for progress. Investors should gradually exit the stock if it continues to rise on the way to the EUR 6 mark. The Company's valuation, profitability and risk structure simply do not match.

    MARBLE FINANCIAL INC - Feel-good factor

    At Canadian fintech Marble Financial Inc, everything revolves around the "financial wellness" of its customers. The Vancouver-based Company has created MyMarble, an innovative, data-driven and personalized platform that helps Canadians manage debt and improve their credit scores. Directly derived from this, users benefit through cheaper loans or rebuilding a credit score. In general, the platform also helps create individual budgets and track progress towards realizing personalized financial goals. The platform also relies heavily on the (further) education of users.

    Marble reports on new collaborations and partnerships almost every week. Strategically, the Company aims to establish itself as a leader in the financial wellness space by embedding itself in an extensive, growing network. Last week, the Canadians reported on its first white-label distribution agreement with Canadian Financial, which has real added value for users. Users will now have access to the credit provider's broad network. Both companies are united by the motivation to inform and educate consumers from previously underserved groups and provide them with greater financial flexibility.

    The innovative Company has achieved necessary financing steps in recent months. Marble wants to grow with a clear profile and is continuously expanding its network. Gradually, this will also be monetized. With a stock market value of CAD 20 million, the Company is very moderately valued.

    ZALANDO SE - Major shareholder wants to exit completely

    Not only the customers could scream with happiness in recent months, but the shareholders too. Last week, Zalando's shares reached a new all-time high of just under EUR 103. Then, the major shareholder, the Swedish investment Company Kinnevik, announced that it would let the Annual General Meeting in April vote on Zalando shares' distribution as a dividend. The transaction is then expected to be completed in Q2. Around half of the voting rights holders have already signaled their support for these plans, the Swedes reported.

    At risk is the 21% stake Kinnevik holds in the Berlin-based company, which is currently worth around EUR 5 billion. The plan has so far caused the share price to correct by around 10%. In 2010 the Swedes had invested in Zalando, which was founded in 2008. Now, after a very successful investment, they want to put the funds into other projects.

    It may well be that the share corrects in the next few months. It is likely that the "Zalando dividend" will be realized by Kinnevik shareholders, creating selling pressure. The current price targets from UBS and Baader Bank of EUR 117 and EUR 115, respectively, indicate where the stock might go again soon.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read